Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP874212.RAg3X95MVp37M9M8O9AQ1UOsRpSY1p-Dx8omV-ug-V_vM130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP874212.RAg3X95MVp37M9M8O9AQ1UOsRpSY1p-Dx8omV-ug-V_vM130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP874212.RAg3X95MVp37M9M8O9AQ1UOsRpSY1p-Dx8omV-ug-V_vM130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP874212.RAg3X95MVp37M9M8O9AQ1UOsRpSY1p-Dx8omV-ug-V_vM130_provenance.
- NP874212.RAg3X95MVp37M9M8O9AQ1UOsRpSY1p-Dx8omV-ug-V_vM130_assertion description "[In this article we describe the variants in genes that influence either the efficacy or toxicity of common drugs used in the treatment of inflammatory bowel diseases (IBD), ulcerative colitis (UC), and Crohn's disease (CD) including sulfasalazine and mesalazine, azathioprine (AZA) and 6-mercaptopurine (6-MP), methotrexate (MTX), glucocorticosteroids (CSs) and infliximab.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP874212.RAg3X95MVp37M9M8O9AQ1UOsRpSY1p-Dx8omV-ug-V_vM130_provenance.
- NP874212.RAg3X95MVp37M9M8O9AQ1UOsRpSY1p-Dx8omV-ug-V_vM130_assertion evidence source_evidence_literature NP874212.RAg3X95MVp37M9M8O9AQ1UOsRpSY1p-Dx8omV-ug-V_vM130_provenance.
- NP874212.RAg3X95MVp37M9M8O9AQ1UOsRpSY1p-Dx8omV-ug-V_vM130_assertion SIO_000772 16773681 NP874212.RAg3X95MVp37M9M8O9AQ1UOsRpSY1p-Dx8omV-ug-V_vM130_provenance.
- NP874212.RAg3X95MVp37M9M8O9AQ1UOsRpSY1p-Dx8omV-ug-V_vM130_assertion wasDerivedFrom befree-20140225 NP874212.RAg3X95MVp37M9M8O9AQ1UOsRpSY1p-Dx8omV-ug-V_vM130_provenance.
- NP874212.RAg3X95MVp37M9M8O9AQ1UOsRpSY1p-Dx8omV-ug-V_vM130_assertion wasGeneratedBy ECO_0000203 NP874212.RAg3X95MVp37M9M8O9AQ1UOsRpSY1p-Dx8omV-ug-V_vM130_provenance.
- befree-20140225 importedOn "2014-02-25" NP874212.RAg3X95MVp37M9M8O9AQ1UOsRpSY1p-Dx8omV-ug-V_vM130_provenance.